Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05464823
NCT05464823Active, not recruitingNot Applicable

Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma

M.D. Anderson Cancer Center1 site in 1 country111 target enrollmentStarted: July 7, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
111
Locations
1
Primary Endpoint
Percentage of participants who have genomic test results available in <=7 days
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Detailed Description

Primary Objective:

• To determine the feasibility and turnaround of clinical WES and transcriptome sequencing

Secondary Objectives:

  • To determine the frequency of actionable DNA and RNA alterations
  • To determine the concordance of DNA and RNA alterations
  • To determine the frequency of molecularly matched therapy
  • To determine the feasibility of identifying mechanism(s) of acquired resistance with genomic profiling
  • To determine the feasibility of molecularly matched therapy to acquired resistance alterations

Exploratory Objectives:

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patient Eligibility:
  • •Inclusion Criteria:
  • •Male/female patients who are at least 18 years of age on the day of informed consent signing.
  • •Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
  • •Provision of written informed consent for the study.

Exclusion Criteria

  • Not provided

Arms & Interventions

Molecular Testing

Other

Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Intervention: Molecular Functional Portrait (Other)

Outcomes

Primary Outcomes

Percentage of participants who have genomic test results available in <=7 days

Time Frame: through study completion an average of 1 year

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
Biomarkers and Functional Imaging in Predicting Response of Esophageal CancerEsophageal Cancer
NCT03029793Air Force Military Medical University, China200
Unknown
Not Applicable
Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）Salivary Gland Neoplasms
NCT05087706Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University182
Terminated
Not Applicable
Functional Image and Molecular Markers to Predict Treatment Outcomes in Lung CancerLung Neoplasms
NCT02117440Indiana University10
Completed
Not Applicable
Stage III NSCLC RWE in Chinese PatientsCarcinoma, Non-Small-Cell Lung
NCT04023812AstraZeneca500
Completed
Not Applicable
PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLCCarcinoma, Non-Small-Cell Lung
NCT02777658AstraZeneca169